This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y
by Zacks Equity Research
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
Halozyme (HALO) Stock Down Despite Q1 Earnings & Sales Beat
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and sales beat estimates. The company retains 2021 guidance.
ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.
Exelixis (EXEL) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) missed on earnings in the first quarter but beats on revenues.
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
by Zacks Equity Research
Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.
Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.
Ionis (IONS) Q1 Loss Widens Year Over Year, Sales Miss
by Zacks Equity Research
Ionis (IONS) Q1 adjusted loss per share was wider than the year-ago figure. The company maintains its guidance for 2021.
AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance
by Zacks Equity Research
AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.
Blueprint Medicines (BPMC) Q1 Earnings Beat, Revenues Lag
by Zacks Equity Research
Blueprint Medicines' (BPMC) beat estimates for earnings in the first quarter of 2021 while revenues miss the same.
Seagen (SGEN) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Seagen (SGEN) lags estimates for earnings and revenues in the first quarter of 2021. Shares lose ground in after-hour trading.
TEVA Beats on Q1 Earnings and Sales, Keeps View, Stock Down
by Zacks Equity Research
TEVA beats on first-quarter earnings and sales. Sales & profits decline year over year. Keeps 2021 view.
Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings
by Zacks Equity Research
AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.
Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down
by Zacks Equity Research
Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.
Pharma Stock Roundup: JNJ's Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates
by Kinjel Shah
J&J (JNJ) beats Q1 estimates for earnings and sales. Roche (RHHBY) announces Q1 sales numbers.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.
Biogen (BIIB) Q1 Earnings Top, Sales Down as Key Drugs Falter
by Zacks Equity Research
Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.
Roche (RHHBY) Q1 Sales Affected by Biosimilars & COVID-19
by Zacks Equity Research
Roche's (RHHBY) performance in the first quarter of 2021 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Bristol Myers (BMY) Opdivo Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval for Opdivo in combination with chemotherapy for patients with gastric cancer, among others.
Sanofi (SNY) Gets Label Expansion Nod for Sarclisa in Europe
by Zacks Equity Research
Sanofi's (SNY) new cancer drug, Sarclisa, gets second approval for treating multiple myeloma patients in Europe within a year.
Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?
by Zacks Equity Research
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.